Prograf marks the first launch for Astellas's Indian subsidiary
This article was originally published in Scrip
Executive Summary
Astellas has launched its global mainstay product, the immunosuppressant Prograf (tacrolimus), in India, marking a step forward for the Japanese company in this major developing market.
You may also be interested in...
Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Pfizer Joins Singapore Initiative To Support Regional Startups
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Need a specific report? 1000+ reports available
Buy Reports